| Literature DB >> 25104165 |
Yu Cheng1, Qing Dai, Ramin A Morshed, Xiaobing Fan, Michelle L Wegscheid, Derek A Wainwright, Yu Han, Lingjiao Zhang, Brenda Auffinger, Alex L Tobias, Esther Rincón, Bart Thaci, Atique U Ahmed, Peter C Warnke, Chuan He, Maciej S Lesniak.
Abstract
The blood-brain barrier (BBB) remains a formidable obstacle in medicine, preventing efficient penetration of chemotherapeutic and diagnostic agents to malignant gliomas. Here, a transactivator of transcription (TAT) peptide-modified gold nanoparticle platform (TAT-Au NP) with a 5 nm core size is demonstrated to be capable of crossing the BBB efficiently and delivering cargoes such as the anticancer drug doxorubicin (Dox) and Gd(3+) contrast agents to brain tumor tissues. Treatment of mice bearing intracranial glioma xenografts with pH-sensitive Dox-conjugated TAT-Au NPs via a single intravenous administration leads to significant survival benefit when compared to the free Dox. Furthermore, it is demonstrated that TAT-Au NPs are capable of delivering Gd(3+) chelates for enhanced brain tumor imaging with a prolonged retention time of Gd(3+) when compared to the free Gd(3+) chelates. Collectively, these results show promising applications of the TAT-Au NPs for enhanced malignant brain tumor therapy and non-invasive imaging.Entities:
Keywords: TAT peptide; blood-brain barrier; brain cancer; doxorubicin; gadolinium; gold nanoparticles; malignant glioma
Mesh:
Substances:
Year: 2014 PMID: 25104165 PMCID: PMC4268041 DOI: 10.1002/smll.201400654
Source DB: PubMed Journal: Small ISSN: 1613-6810 Impact factor: 13.281